These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22155899)

  • 21. Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.
    Trezza CR; Kashuba AD
    Clin Pharmacokinet; 2014 Jul; 53(7):611-24. PubMed ID: 24859035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Characteristics of antiretroviral drugs].
    Ribera E; Tuset M; Martín M; del Cacho E
    Enferm Infecc Microbiol Clin; 2011 May; 29(5):362-91. PubMed ID: 21531048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of antiretroviral drugs.
    Hoetelmans RM
    Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
    Taiwo B; Murphy RL; Katlama C
    Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
    van Praag RM; Weverling GJ; Portegies P; Jurriaans S; Zhou XJ; Turner-Foisy ML; Sommadossi JP; Burger DM; Lange JM; Hoetelmans RM; Prins JM
    AIDS; 2000 Jun; 14(9):1187-94. PubMed ID: 10894283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
    Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
    HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging anti-HIV drugs.
    De Clercq E
    Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.
    Solas C; Lafeuillade A; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    Antimicrob Agents Chemother; 2003 Jan; 47(1):238-43. PubMed ID: 12499197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV exposure through contact with body fluids.
    Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
    van Praag RM; van Heeswijk RP; Jurriaans S; Lange JM; Hoetelmans RM; Prins JM
    Clin Infect Dis; 2001 Oct; 33(8):e91-2. PubMed ID: 11565093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
    Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
    Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.